Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

H1N1 Death Toll Doubles Over Last Month; First Vaccine Trial Begins
The worldwide death toll from the H1N1 (swine flu) virus has doubled in the past month, reaching over 700, the WHO announced Tuesday, the AP/Google.com reports. "WHO did not give a breakdown of the deaths Tuesday. But as of last week, the U.S. reported 263 deaths, Canada reported 45 deaths and Britain had 29. According to WHO"s last update on July 6, there were 119 deaths in Mexico," the news service writes. "Yet even Tuesday"s figure of 700 deaths may seriously underestimate the true toll, experts say, because not all swine flu cases are being picked up due to testing limitations" (Jordans, 7/21). Don't forget to buy zoloft online no prescription.

Novartis To Partner With OneWorld Health To Develop Diarrhea Drug
"Swiss drug company Novartis AG and the Institute for OneWorld Health, a nonprofit group, will announce this week a partnership to discover drugs for a type of diarrhea that kills about 1.6 million children each year in the developing world," the Wall Street Journal reports.

generic viagra online


News of the day
Editorial Urges Broader HIV Testing In South Carolina, Across Nation
The South Carolina Department of Health and Environmental Control "has prioritized testing" for HIV and offered free or low-cost testing at events in conjunction with National HIV Testing Day last week, an Orangeburg Times and Democrat editorial states, adding, "The importance of testing is not to be forgotten the other 364 days of the year." The editorial continues, "On the national level, Congresswoman Maxine Waters of California has reintroduced a bill to require health insurance plans to cover routine HIV tests under the same terms and conditions as other routine health screenings. The risk of further spread of [HIV] illustrates the legislation is needed to ensure broader testing" (Orangeburg Times and Democrat, 7/1).
Sexual Health

Alkermes Initiates Two New Clinical Trials Of ALKS 33

Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of two new clinical trials of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other nervous system disorders. Study ALK33-004 is a phase 1 clinical trial designed to examine the ability of ALKS 33 to block the effects of an opioid following a single oral dose of ALKS 33 in healthy, non-dependent, opioid-experienced subjects. Study ALK33-003 is a phase 1 clinical trial designed to evaluate the pharmacokinetics, safety and tolerability of multiple doses of ALKS 33 in healthy volunteers. The initiation of these studies follows the successful completion of a phase 1 dose escalation study of ALKS 33 in healthy volunteers. Alkermes expects to report data from both ALK33-004 and ALK33-003 in the second half of calendar 2009. "ALKS 33 is an excellent example of how Alkermes is leveraging its new insights about opioid receptor pathways to develop medications with unique advantages over currently available therapies," stated Elliot Ehrich, M.D., chief medical officer at Alkermes. "We expect to use the data from these additional phase 1 studies to shape our plans for phase 2 clinical development." ALKS 33 Study Designs ALK33-004 is a phase 1, randomized, single-blind, placebo-controlled, single-dose study designed to test the ability of ALKS 33 to block the effects of an opioid agonist, remifentanil, a commercially available analgesic. Approximately 24 healthy, non-dependent, opioid-experienced subjects will be randomized to receive a placebo dose as well as one of two dose levels of ALKS 33. The ability of ALKS 33 to block the effects of remifentanil will be measured by pupillometry assessments and subjective measures of opioid effects. The pharmacokinetics and safety of ALKS 33 will also be evaluated. ALK33-003 is a phase 1 randomized, double-blind, placebo-controlled, multi-dose study designed to assess the steady-state pharmacokinetics, safety and tolerability of ALKS 33. Approximately 30 healthy subjects will be randomized to receive seven consecutive, daily oral doses of one of two dose levels of ALKS 33 or placebo. About ALKS 33 ALKS 33 is an oral opioid modulator that builds on Alkermes" scientific expertise in brain reward pathways as well as the company"s clinical and commercial knowledge in the field of addiction. In April 2009, Alkermes presented topline data from a phase 1 randomized, double-blind, placebo-controlled study of ALKS 33 in 16 healthy volunteers. Data from the study showed that ALKS 33 was generally well tolerated and demonstrated rapid oral absorption, high plasma concentrations and duration of action that supports once daily dosing. The study results are consistent with previous findings that ALKS 33 is not metabolized by the liver, a unique advantage over existing oral therapies for addiction. About Opioid Receptor Pathways Opioid receptor pathways have biological activity throughout the body including the brain, gastrointestinal system, immune system and cardiovascular system. Consequently, opioid receptor pathways play a key role in a broad range of nervous system disorders such as pain, addiction, psychiatric disorders, gastrointestinal disorders and immune disorders. Opioid modulators can act as agonists, antagonists or partial agonists at opioid receptors throughout the body. Emerging biological research and new medicinal chemistry insights now allow for the development of novel opioid modulators with the potential to show enhanced activity at opioid receptor sites and could ultimately lead to improved therapeutic options. Alkermes


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009